Liafensine

Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Mental Health, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, Dopamine, Depression, Liafensine, SDS, Serotonin, MDD, Patient, CNS, Biomarker, DSM-IV codes, Overalls, Medicine, TRD, Safety, Norepinephrine, MADRS, Pharmaceutical industry

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).

Key Points: 
  • Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).
  • More than 23 million people in the U.S. alone suffer from major depressive disorder (MDD).
  • TRD remains a highly unmet medical need indication as there are few approved pharmacological agents for TRD and overall, outcomes remain poor.
  • Using its unique big data based Denovo Genomic Marker (DGM™) biomarker platform, Denovo discovered a novel genetic biomarker, termed DGM4™, which was hypothesized to predict liafensine’s efficacy in TRD patients.